Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 18Lymphoid 4Plasma cell 3CNS 3Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Gastrointestinal 1

Conditions

Lymphoma, Large-Cell, Anaplastic 2Granuloma, Plasma Cell 2Rhabdomyosarcoma 1Neuroblastoma 1Neoplasms 1Hematologic Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Temozolomide 123Radiotherapy 47Bevacizumab 46Lomustine 25Radiation 20Nivolumab 17Irinotecan 16Carboplatin 16Cyclophosphamide 14Granulocyte-Macrophage Colony-Stimulating Factor 13pembrolizumab 11dabrafenib 10Trastuzumab 10Surgical Procedures, Operative 10Capecitabine 10paclitaxel-Angiopep-2 conjugate 8TIC10 compound 8Paclitaxel 8Gemcitabine 8Carmustine 8trametinib 7Topotecan 7IL13-PE38 7Everolimus 7Drug Therapy 7Aminolevulinic Acid 7AZD 6244 73-Iodobenzylguanidine 7fludarabine 6enzastaurin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × ceritinib × CNS × Clear all
NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Novartis

Phase 1 Completed
83 enrolled 30 charts
CNSLymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

NCT02336451 2020-04-21

Ascend-7

Novartis

Phase 2 Completed
156 enrolled 39 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡